Background: transcatheter aortic valve replacement (TAVR) provides prognostic benefit for high surgical-risk patients with severe aortic stenosis (AS), yet the impact to patient outcomes is far less understood. Method: we performed a systematic review and meta-analysis to evaluate functional capacity and health-related quality of life (HRQoL) outcomes for patients up to 12 months post TAVR. A total of 20 eligible publications, comprising randomised-controlled trials, observational studies and a registry study were identified from electronic databases, including MEDLINE, EMBASE, Cochrane Library and others (inception to February 2017). Results: the total sample was 2,775 with a mean age of 81.8 ± 2.1 years, more than half (52%) were female and high surgical risk 9.6 ± 4.3% mean STS (Society of Thoracic Surgeons risk model). Post TAVR, patients had significant improvement in functional capacity of >40 m in the 6-minute walk test (6MWT) (95% confidence interval (CI) 9.69-73.28) and a clinically meaningful increase in ability to perform daily physical-based tasks (Duke Activity Status Index (DASI), mean difference (MD) increase 5.42 points, 95% CI 3.16-7.68). HRQoL improved consistently following TAVR regardless of measure used. Significant increases occurred in the physical component summary scores (PCS) of the short form (SF) health surveys (MD increase 10.45 (SF36) and 10.14 (SF12) points). Conclusion: functional capacity and HRQoL improved substantially following TAVR, despite evolving patient selection criteria, thus TAVR continues to provide a directly beneficial option for severe AS patients.
Introduction
Aortic Stenosis (AS) is one of the most common heart valve diseases globally and numbers are forecast to increase alongside aging populations. One treatment strategy for severe AS patients of high surgical risk is Transcatheter Aortic Valve Implantation (TAVR). TAVR has inherent advantages of minimally invasive procedures and not surprisingly often preferred by older patients [1] . The impact of TAVR on patient outcomes other than mortality has had minimal investigation to date, which is surprising given the value older patients place on functional capacity and healthrelated quality of life (HRQoL) [2] . While HRQoL is receiving increasing attention [3, 4] , few studies include functional capacity changes [5] , except often via limited symptom classification. This systematic review and meta-analysis aims to investigate both functional capacity and HRQoL outcomes from TAVR, to understand the effect upon daily life for older patients.
Methods
Eligibility criteria and search strategy
The review was guided by Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) [6] . A systematic search was conducted of the literature on functional capacity and HRQoL outcomes for TAVR patients in the following databases: CINAHL, EMB Review, EMBASE, Where multiple studies assessed the same sample the most complete reporting of outcomes was used. Two authors (NS, RG) screened and reviewed reports and a third author (RB) made the decision when uncertainty occurred. Only studies published in English and reporting data collected via valid measures of functional capacity and/or HRQoL, pre-and up to 12 months post TAVR were included. Data from the furthest follow-up time point was used for comparison to baseline. No paper was excluded on the basis of quality assessment. 
Statistical analysis

Results
Study characteristics
This review included 20 studies, with an overall sample of 2,775 patients (Table 1 ). Participants had a mean age of 81.8 ± 2.1 years, females constituted 52.3% ± 8.6% and the mean STS score was 9.6 ± 4.3%, indicating a high-risk patient group. Measures of functional capacity included 6MWT (n = 5) and DASI (n = 3), and for HRQoL, SF12/ 36 (n = 10), EuroQoL-5D (EQ5D) (n = 6), Minnesota Living with Heart Failure Questionnaire (MLHFQ) (n = 3) and lastly Kansas City Cardiomyopathy Questionnaire (KCCQ) (n = 4).
Functional capacity
Functional capacity improved significantly post TAVR with 4 [11, 14, 19, 22] Figure 3 available in Age and Ageing online), the latter classified as clinically meaningful. Cross study heterogeneity was present for functional capacity with a moderate to significant range of I 2 = 59% (DASI) to I 2 = 85% (6MWT).
Health-related quality of life
HRQoL improved post TAVR irrespective of the measure utilised. Of the 17 studies which measured HRQoL (Table 1) , 15 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] reported significant improvements post TAVR. Improvements were clinically meaningful in the studies using SF12, SF36 and MLHFQ. Substantial improvements occurred in the PCS, with MD increases of 10.45 points (CI 4.85-16.06, P = 0.01) (Figure 1 ) and 10.14 points (CI 4.20-16.09, P = 0.01) (SF12). Psychological well-being in the mental composite component (MCS) also improved meaningfully, although to a lesser extent, with MD increases of 3.45 points (CI 0.82-7.90, P = 0.11) (SF36) and 5.95 points (CI 2.80-9.09, P = 0.01) (SF12 
Discussion
Our systematic review and meta-analyses identified substantial improvements post TAVR in functional capacity and HRQoL for severe AS patients. TAVR provides significant benefits in overall and cardiac-specific quality of life and importantly physical capability, providing the potential for patients to maintain independence in their own environments. The findings of this review, which include an additional seven studies to the most recent review by Kim et al.
(2014) [3] contribute to the evidence that TAVR improves HRQoL regardless of evolving patient selection processes and different contexts [3, 4] , and that corresponding improvements occur for functional capacity. Several contemporary findings from this review lend support to the changing patient population for TAVR. For instance, recent studies indicate patients have better functional capacity and HRQoL at baseline than initial studies [22] [23] [24] [25] [26] . Changes in patient surgical-risk characteristics have also occurred, from initial extremely high surgical-risk patients (STS 18.1%) [7] being enroled into initial TAVR studies, to recently more intermediate-risk (STS 5.1%) [26] , indicative of changing perception of TAVR as a treatment option for AS.
An important objective of TAVR is to reduce the physical limitations imposed upon patients by their symptoms, aside from improved mortality alone. Functional capacity is strongly linked to independence for older people [27] . To our knowledge this is the first meta-analysis to explore this outcome in high-risk TAVR patients. Functional capacity improved both in terms of objectively measured exercise capacity (6MWT) and as a self-reported energy-expenditure (DASI) post TAVR. An improvement in exercise capacity even by 40 m, would enable more overall physical competence. In contrast to our findings, severe AS patients undergoing SAVR of low to intermediate surgical risk (Auensen et al. 2017) [28] , are reported to have decreases in 6MWT by an average of 22 m from baseline to 1-year post procedure. Furthermore, TAVR patients from our review reported greater incremental physical quality of life improvements long term, in comparison to SAVR patients from a recent study by Jansen Klomp et al. (2016) [29] .
In combination with HRQoL improvements post TAVR, functional capacity measures have great value when used pre-procedure to assist in discriminating future health and function in of older people and further research is needed in this area.
Study limitations
High heterogeneity occurred amongst our studies, reflecting the diversity of samples and methods included, the majority being single-centre observational studies (65%). In addition, the meta-analysis of each outcome was only performed on a small number of studies, highlighting the limited data currently available. A consequence is that we were unable to perform multiple time-point assessments of each outcome.
Conclusion
As TAVR therapy evolves and the patient selection criteria broadens to treat lower risk groups, this review provides evidence that benefits for functional capacity and HRQoL have been maintained. The use of both measures also ensures a more nuanced understanding of outcomes and an expanded description of expected benefits to patients. Importantly, our review provides a contemporary benchmark to be considered for future TAVR patients.
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